The relationship between allergen immunotherapy and omalizumab for treating asthma

Fulvio Braido, Angelo Corsico, Anthi Rogkakou, Vanessa Ronzoni, Ilaria Baiardini, Giorgio Walter Canonica

Research output: Contribution to journalArticle

Abstract

Allergen-specific immunotherapy (AIT) is considered the only treatment capable of modifying the natural history of allergic respiratory disorders. The possible adverse events related to AIT have, until now, limited its use to mild and controlled asthma. The pre-administration or concomitant treatment of AIT and omalizumab (an anti-IgE humanized antibody), recommended for the treatment of severe allergic asthma, could be useful in reducing the adverse events due to AIT and to allow its use in patients with more severe or uncontrolled asthma. AIT/omalizumab combination has been explored in a few trials on asthma patients and also in other allergic disorders, such as rhinitis, hymenoptera systemic reaction and food allergy with significant results. We are at the beginning a new era where phenotype/endotype-based treatment will be associated with drug mass therapy and/or nonpharmacological phenotype/endotype-driven treatment to optimize disease control and/or to make the use of other treatments safer.

Original languageEnglish
Pages (from-to)129-134
Number of pages6
JournalExpert Review of Respiratory Medicine
Volume9
Issue number2
DOIs
Publication statusPublished - Apr 1 2015

Fingerprint

Immunologic Desensitization
Asthma
Therapeutics
Phenotype
Antibodies, Monoclonal, Humanized
Hymenoptera
Food Hypersensitivity
Rhinitis
Natural History
Omalizumab
Drug Therapy

Keywords

  • asthma
  • IgE
  • omalizumab
  • outcomes
  • specific immunotherapy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Immunology and Allergy
  • Public Health, Environmental and Occupational Health
  • Medicine(all)

Cite this

The relationship between allergen immunotherapy and omalizumab for treating asthma. / Braido, Fulvio; Corsico, Angelo; Rogkakou, Anthi; Ronzoni, Vanessa; Baiardini, Ilaria; Canonica, Giorgio Walter.

In: Expert Review of Respiratory Medicine, Vol. 9, No. 2, 01.04.2015, p. 129-134.

Research output: Contribution to journalArticle

Braido, Fulvio ; Corsico, Angelo ; Rogkakou, Anthi ; Ronzoni, Vanessa ; Baiardini, Ilaria ; Canonica, Giorgio Walter. / The relationship between allergen immunotherapy and omalizumab for treating asthma. In: Expert Review of Respiratory Medicine. 2015 ; Vol. 9, No. 2. pp. 129-134.
@article{64e1c476458745cc9a3dead6b0c921b5,
title = "The relationship between allergen immunotherapy and omalizumab for treating asthma",
abstract = "Allergen-specific immunotherapy (AIT) is considered the only treatment capable of modifying the natural history of allergic respiratory disorders. The possible adverse events related to AIT have, until now, limited its use to mild and controlled asthma. The pre-administration or concomitant treatment of AIT and omalizumab (an anti-IgE humanized antibody), recommended for the treatment of severe allergic asthma, could be useful in reducing the adverse events due to AIT and to allow its use in patients with more severe or uncontrolled asthma. AIT/omalizumab combination has been explored in a few trials on asthma patients and also in other allergic disorders, such as rhinitis, hymenoptera systemic reaction and food allergy with significant results. We are at the beginning a new era where phenotype/endotype-based treatment will be associated with drug mass therapy and/or nonpharmacological phenotype/endotype-driven treatment to optimize disease control and/or to make the use of other treatments safer.",
keywords = "asthma, IgE, omalizumab, outcomes, specific immunotherapy",
author = "Fulvio Braido and Angelo Corsico and Anthi Rogkakou and Vanessa Ronzoni and Ilaria Baiardini and Canonica, {Giorgio Walter}",
year = "2015",
month = "4",
day = "1",
doi = "10.1586/17476348.2015.1000866",
language = "English",
volume = "9",
pages = "129--134",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "2",

}

TY - JOUR

T1 - The relationship between allergen immunotherapy and omalizumab for treating asthma

AU - Braido, Fulvio

AU - Corsico, Angelo

AU - Rogkakou, Anthi

AU - Ronzoni, Vanessa

AU - Baiardini, Ilaria

AU - Canonica, Giorgio Walter

PY - 2015/4/1

Y1 - 2015/4/1

N2 - Allergen-specific immunotherapy (AIT) is considered the only treatment capable of modifying the natural history of allergic respiratory disorders. The possible adverse events related to AIT have, until now, limited its use to mild and controlled asthma. The pre-administration or concomitant treatment of AIT and omalizumab (an anti-IgE humanized antibody), recommended for the treatment of severe allergic asthma, could be useful in reducing the adverse events due to AIT and to allow its use in patients with more severe or uncontrolled asthma. AIT/omalizumab combination has been explored in a few trials on asthma patients and also in other allergic disorders, such as rhinitis, hymenoptera systemic reaction and food allergy with significant results. We are at the beginning a new era where phenotype/endotype-based treatment will be associated with drug mass therapy and/or nonpharmacological phenotype/endotype-driven treatment to optimize disease control and/or to make the use of other treatments safer.

AB - Allergen-specific immunotherapy (AIT) is considered the only treatment capable of modifying the natural history of allergic respiratory disorders. The possible adverse events related to AIT have, until now, limited its use to mild and controlled asthma. The pre-administration or concomitant treatment of AIT and omalizumab (an anti-IgE humanized antibody), recommended for the treatment of severe allergic asthma, could be useful in reducing the adverse events due to AIT and to allow its use in patients with more severe or uncontrolled asthma. AIT/omalizumab combination has been explored in a few trials on asthma patients and also in other allergic disorders, such as rhinitis, hymenoptera systemic reaction and food allergy with significant results. We are at the beginning a new era where phenotype/endotype-based treatment will be associated with drug mass therapy and/or nonpharmacological phenotype/endotype-driven treatment to optimize disease control and/or to make the use of other treatments safer.

KW - asthma

KW - IgE

KW - omalizumab

KW - outcomes

KW - specific immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=84925010869&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925010869&partnerID=8YFLogxK

U2 - 10.1586/17476348.2015.1000866

DO - 10.1586/17476348.2015.1000866

M3 - Article

C2 - 25578528

AN - SCOPUS:84925010869

VL - 9

SP - 129

EP - 134

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 2

ER -